A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR

Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE® Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications

(2014) Lindsey M. Hoffman et al.   Frontiers in Oncology

Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

(2013) Y. Kienast et al.   CLINICAL CANCER RESEARCH

A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity

(2013) Wenlong Tan et al.   mAbs

Antibody Therapeutics in Cancer

(2013) M. X. Sliwkowski et al.   SCIENCE

Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway

(2012) J. Honeychurch et al.   BLOOD

Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells

(2012) S.-R. Kuo et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Preclinical studies on targeted delivery of multiple IFN 2b to HLA-DR in diverse hematologic cancers

(2011) E. A. Rossi et al.   BLOOD

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

(2011) W. Alduaij et al.   BLOOD

Bispecific Antibodies for Cancer Immunotherapy

(2010) Dafne Müller et al.   BIODRUGS

Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways

(2010) R. Stein et al.   BLOOD

HLA-DR meets ERK

(2010) E. Hertlein et al.   BLOOD

A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin

(2010) Geng Kou et al.   CANCER LETTERS

A Bispecific Antibody-IFN 2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells

(2010) E. A. Rossi et al.   CANCER RESEARCH

Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16

(2010) Heiko Singer et al.   JOURNAL OF IMMUNOTHERAPY

Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma

(2010) Rhona Stein et al.   LEUKEMIA & LYMPHOMA

Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules

(2010) Chengbin Wu et al.   mAbs

Monoclonal antibodies for cancer immunotherapy

(2009) Louis M Weiner et al.   LANCET

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

(2008) Bruce D. Cheson et al.   NEW ENGLAND JOURNAL OF MEDICINE